Additionally, large, randomized studies recently reported that the addition of bevacizumab to EGFR tyrosine kinase inhibitors (TKIs) substantially improved PFS in patients with EGFR-mutant NSCLC [15, 16]. Here, EGFR is linked to non-small cell lung carcinoma.